Did a Sickle Cell Study Establish That Cannabis Caused More Hospitalizations?

A study title can sound causal even when the design compares observational groups. A 2017 sickle cell disease report examined cannabis-screen findings and health-service use in a small clinical cohort.

What the study compared

The retrospective analysis included 72 patients and 270 urine tests. Thirty-seven patients were classified as cannabinoid-positive and thirty-five as negative. The paper reported more hospital admissions for vaso-occlusive crises in the cannabis group, fewer clinic visits, and no significant difference in emergency-department admissions.

Which group differences mattered?

Cannabinoid-positive patients also had more positive findings for benzodiazepines, cocaine, and phencyclidine. Male cannabis users were younger than male nonusers. Patients who tested positive reported smoking for pain relief and other reasons. Disease severity and reasons for use could therefore influence the observed relationship with hospitalization.

How to interpret exposure and causation

A urine result documents detection under the test’s conditions. It supplies limited information about the amount used, the timing relative to an admission, or impairment at that time. The repeated tests also included fluctuations between positive and negative findings in some patients. The study’s association should be evaluated with those exposure limits and group differences intact. For an attorney reviewing a cannabis-related claim, distinguish recorded detection, reported purpose of use, underlying disease, other substances, and the specific outcome. This historical cohort raises questions for controlled investigation while leaving the independent effect of cannabis on admissions unresolved.

Source

Read the full scientific paper. DOI 10.1089/can.2017.0011.